Nasdaq · CIK 0001619856
CRBU Caribou Biosciences, Inc.
Insider trading from SEC Form 4. Last filing Feb 24, 2026. Close $0.46 on Oct 9, 2026, 0% from the 52-week low and -84% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
15
with a Form 4 at this company
Price and insider trades, last year
CRBUOct 9, 2026 · close 0.46
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Caribou Biosciences, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Tina M. Albertson Chief Medical Officer sell | $2,089 1,066 shares | -2% | +192% from low-25% from high | |
| 20Weak | Rachel E. Haurwitz President and CEO buy | $20k 20,000 shares | +1% | - | |
| 10Weak | Barbara G McClung Chief Legal Officer sell | $4,811 3,564 shares | -1% | - | |
| 10Weak | Steven Kanner Chief Scientific Officer sell | $4,811 3,564 shares | -1% | - | |
| 10Weak | Ruhi Ahmad Khan Chief Business Officer sell | $4,811 3,564 shares | -5% | - | |
| 30Weak | Sriram Ryali Chief Financial Officer buy | $25k 17,360 shares | - | - |
Transactions
The last 30 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 20, 2026 | Tina M. Albertson Chief Medical Officer | AGrant or award Common Stock10b5-1 | +55,000 | $0.00 | $0 | 69,589 | Feb 24, 2026 |
| Feb 24, 2026 | Tina M. Albertson Chief Medical Officer | SOpen-market sale Common Stock10b5-1 | -1,066 | $1.96 | $2,089 | 68,523 | Feb 24, 2026 |
| Feb 20, 2026 | Tina M. Albertson Chief Medical Officer | AGrant or award Option to purchase Common Stockderivative10b5-1 | +247,500 | $0.00 | $0 | 247,500 | Feb 24, 2026 |
| Feb 20, 2026 | Scott Braunstein director | AGrant or award Option to purchase Common Stockderivative | +45,000 | $0.00 | $0 | 45,000 | Feb 20, 2026 |
| Mar 14, 2025 | Rachel E. Haurwitz President and CEO | POpen-market purchase Common Stockindirect: By Trust | +20,000 | $1.02 | $20k | 3,369,395 | Mar 17, 2025 |
| Feb 20, 2025 | Ruhi Ahmad Khan Chief Business Officer | AGrant or award Common Stock | +37,500 | $0.00 | $0 | 70,500 | Feb 21, 2025 |
| Feb 20, 2025 | Ran Zheng director | AGrant or award Option to purchase Common Stockderivative | +40,500 | $0.00 | $0 | 40,500 | Feb 21, 2025 |
| Feb 20, 2025 | Nancy Whiting director | AGrant or award Option to purchase Common Stockderivative | +40,500 | $0.00 | $0 | 40,500 | Feb 21, 2025 |
| Feb 20, 2025 | Steven Kanner Chief Scientific Officer | AGrant or award Common Stock | +37,500 | $0.00 | $0 | 435,120 | Feb 21, 2025 |
| Feb 20, 2025 | Timothy P Kelly Chief Technology Officer | AGrant or award Common Stock | +37,500 | $0.00 | $0 | 37,500 | Feb 21, 2025 |
| Feb 20, 2025 | David Lee Johnson director | AGrant or award Option to purchase Common Stockderivative | +40,500 | $0.00 | $0 | 40,500 | Feb 21, 2025 |
| Feb 20, 2025 | Natalie Sacks director | AGrant or award Option to purchase Common Stockderivative | +40,500 | $0.00 | $0 | 40,500 | Feb 21, 2025 |
| Feb 20, 2025 | Rachel E. Haurwitz President and CEO | AGrant or award Common Stock | +136,750 | $0.00 | $0 | 295,450 | Feb 21, 2025 |
| Feb 20, 2025 | Dara Richardson-Heron director | AGrant or award Option to purchase Common Stockderivative | +40,500 | $0.00 | $0 | 40,500 | Feb 21, 2025 |
| Feb 20, 2025 | Barbara G McClung Chief Legal Officer | AGrant or award Common Stock | +37,500 | $0.00 | $0 | 447,066 | Feb 21, 2025 |
| Feb 20, 2025 | Andrew Guggenhime director | AGrant or award Option to purchase Common Stockderivative | +40,500 | $0.00 | $0 | 40,500 | Feb 21, 2025 |
| Feb 20, 2025 | Scott Braunstein director | AGrant or award Option to purchase Common Stockderivative | +40,500 | $0.00 | $0 | 40,500 | Feb 21, 2025 |
| Feb 20, 2025 | Tina M. Albertson Chief Medical Officer | AGrant or award Common Stock | +14,589 | $0.00 | $0 | 14,589 | Feb 21, 2025 |
| Feb 20, 2025 | Tina M. Albertson Chief Medical Officer | AGrant or award Option to purchase Common Stockderivative | +66,137 | $0.00 | $0 | 66,137 | Feb 21, 2025 |
| Feb 20, 2025 | Timothy P Kelly Chief Technology Officer | AGrant or award Option to purchase Common Stockderivative | +170,000 | $0.00 | $0 | 170,000 | Feb 21, 2025 |
| Feb 21, 2025 | Ruhi Ahmad Khan Chief Business Officer | SOpen-market sale Common Stock10b5-1 | -3,564 | $1.35 | $4,811 | 66,936 | Feb 21, 2025 |
| Feb 21, 2025 | Steven Kanner Chief Scientific Officer | SOpen-market sale Common Stock10b5-1 | -3,564 | $1.35 | $4,811 | 431,556 | Feb 21, 2025 |
| Feb 21, 2025 | Barbara G McClung Chief Legal Officer | SOpen-market sale Common Stock10b5-1 | -3,564 | $1.35 | $4,811 | 443,502 | Feb 21, 2025 |
| Feb 20, 2025 | Ruhi Ahmad Khan Chief Business Officer | AGrant or award Option to purchase Common Stockderivative | +170,000 | $0.00 | $0 | 170,000 | Feb 21, 2025 |
| Feb 20, 2025 | Rachel E. Haurwitz President and CEO | AGrant or award Option to purchase Common Stockderivative | +618,250 | $0.00 | $0 | 618,250 | Feb 21, 2025 |
| Feb 20, 2025 | Steven Kanner Chief Scientific Officer | AGrant or award Option to purchase Common Stockderivative | +170,000 | $0.00 | $0 | 170,000 | Feb 21, 2025 |
| Feb 20, 2025 | Barbara G McClung Chief Legal Officer | AGrant or award Option to purchase Common Stockderivative | +170,000 | $0.00 | $0 | 170,000 | Feb 21, 2025 |
| Jan 29, 2025 | Sriram Ryali Chief Financial Officer | POpen-market purchase Common Stock | +17,360 | $1.42 | $25k | 17,360 | Jan 30, 2025 |
| Jan 10, 2025 | Sriram Ryali Chief Financial Officer | AGrant or award Option to purchase Common Stockderivative | +300,000 | $0.00 | $0 | 300,000 | Jan 10, 2025 |
| Nov 20, 2024 | Ryan Fischesser VP of Finance and Controller | AGrant or award Common Stock | +25,000 | $0.00 | $0 | 118,854 | Nov 22, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Tina M. AlbertsonChief Medical Officer
- Scott Braunsteinceo, chair, officer, director
- Ryan FischesserVP of Finance and Controller
- Andrew Guggenhimecfo, president, officer, director
- Rachel E. HaurwitzPresident and CEO
- David Lee Johnsondirector, coo, officer
- Steven KannerChief Scientific Officer
- Timothy P KellyChief Technology Officer
- Ruhi Ahmad KhanChief Business Officer
- Barbara G McClungChief Legal Officer
- Dara Richardson-Herondirector
- Sriram RyaliChief Financial Officer
- Natalie Sacksdirector
- Nancy Whitingdirector
- Ran Zhengdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.